Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Regenera Sciences Ip Lda is currently engaged in patent prosecution within the Biotechnology & Pharmaceuticals technology area. The company's portfolio features 1 pending office action, which is being reviewed in 1 distinct art unit. This indicates a very specific technical focus for the company's current intellectual property efforts in the biotech sector.
The prosecution is managed by 1 distinct examiner, STAVROU, CONSTANTINA E. As the busiest examiner for the portfolio, STAVROU, CONSTANTINA E is responsible for 1 busiest examiner pending office action. This means that the company's immediate success in securing patent rights depends entirely on the specific requirements and interpretation of this single examiner within the 1 distinct art unit.
For a practitioner, this concentration of 1 pending office action under 1 distinct examiner simplifies the management of the portfolio but also increases the impact of a single individual's decisions. There are no other active examiners or art units to provide a baseline for comparison. Therefore, the strategy for Regenera Sciences Ip Lda must be highly tailored to the preferences of STAVROU, CONSTANTINA E to ensure a favorable outcome in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STAVROU, CONSTANTINA E | 1 | 42.4% | +35.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18793848 | COMPOSITIONS FOR USE IN THE TREATMENT OF MUSCULOSKELETAL CONDITIONS AND METHODS FOR PRODUCING THE SAME LEVERAGING THE SYNERGISTIC ACTIVITY OF TWO DIFFERENT TYPES OF MESENCHYMAL STROMAL/STEM CELLS | STAVROU, CONSTANTINA E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18793848 | COMPOSITIONS FOR USE IN THE TREATMENT OF MUSCULOSKELETAL CONDITIONS AND METHODS FOR PRODUCING THE SAME LEVERAGING THE SYNERGISTIC ACTIVITY OF TWO DIFFERENT TYPES OF MESENCHYMAL STROMAL/STEM CELLS | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18793848 | COMPOSITIONS FOR USE IN THE TREATMENT OF MUSCULOSKELETAL CONDITIONS AND METHODS FOR PRODUCING THE SAME LEVERAGING THE SYNERGISTIC ACTIVITY OF TWO DIFFERENT TYPES OF MESENCHYMAL STROMAL/STEM CELLS | STAVROU, CONSTANTINA E | 1632 | §103§112 | Non-Final OA | — | Pending | Aug 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRegenera Sciences Ip Lda has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Constantina E Stavrou has the most, with 1 of Regenera Sciences Ip Lda's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
